| abstract |
The use of a cancerous disease modifying antibody (CDMAB) H460-16-2 for treating a tumor in humans and methods of isolating and identifying cancerous cells which express a CD44 antigenic moiety. The monoclonal antibody H460-16-2 (ATTC accession number PTA-4621), which binds a CD44 antigenic moiety, is cytotoxic to cancer cells, wherein cytotoxicity is mediated via antibody dependent cell mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The monoclonal antibody H460-16-2 is useful for delaying the disease progression of a human tumor. |